Get Cash Back and $0 Commissions + The Power of TradeStation
IntriCon Reports First Quarter 2019 Results
Globe Newswire 29-Apr-2019 4:34 PM
ARDEN HILLS, Minn., April 29, 2019 (GLOBE NEWSWIRE) -- IntriCon Corporation (NASDAQ:IIN), a designer, developer, manufacturer and distributor of miniature and micro-miniature body-worn devices, today announced financial results for its first quarter ended March 31, 2019.
Recent Highlights:
Quarterly revenue of $30.1 million, an 18.7% increase over the prior-year first quarter
Gross margin of 29.1%, compared to 33.2% in the prior-year period
Net income per share of $0.08 versus $0.10 in the 2018 first quarter
Revenue growth from largest medical customer of 26.6% compared to first quarter 2018
Announced changes to Board of Directors, effective May 1, 2019 ? Raymond Huggenberger, former Inogen CEO, appointed as a director ? Michael McKenna retired from his position as Chairman of the Board ? Philip Smith, a current director, elected Chairman of the Board
Announced leadership promotions ? Chief Financial Officer Scott Longval assumed additional responsibilities as Chief Operating Officer ? Michael Geraci named Senior Vice President, Sales and Marketing ? Dennis Gonsior named Senior Vice President, Global Operations ? Greg Gruenhagen named Senior Vice President, Quality and Regulatory Affairs
"We were pleased with our first quarter performance and execution, with progress made on each of the priorities we laid out at the start of the year," said Mark Gorder, President and Chief Executive Officer of IntriCon. "In our Medical business, we continued to benefit from Medtronic's on-going conversion to its MiniMed 670G system, and we were delighted to secure a new, large medical customer for our proprietary medical coils. In our Hearing Health business, we remain very encouraged by the expanding opportunity we see for our value-based hearing solutions and the relationships we maintain with our current partners. In addition, we are excited to pursue new opportunities for growth spurred by the 2017 legislation that will open a significant new over-the-counter market.
"As we look forward, we will continue to meet the volume demands of our key customers and partners, while pursuing new business opportunities that can best leverage our core competencies and global infrastructure in order to accelerate growth and diversify our revenue base," concluded Gorder.
First Quarter 2019 Financial Results For the 2019 first quarter, the company reported net revenue of $30.1 million, up 18.7% from $25.4 million in the comparable prior-year period. The increase was primarily due to year-over-year revenue gains from its diabetes and medical coil markets.
By business line, revenue in IntriCon's Medical business increased 30.5% in the first quarter of 2019 versus the comparable prior-year period. The gain was primarily driven by the ongoing production of wireless continuous glucose monitoring systems as a result of its long-standing relationship with Medtronic's Diabetes division. Revenue to this customer increased 26.6% in the first quarter over the comparable prior-year period.
Hearing Health revenue was relatively flat in the first quarter of 2019 compared to the prior-year first quarter. The modest revenue during the quarter was largely due to the impact of a customer's product cycle in the company's Indirect-to-End-Consumer channel and measured advertising spend in its Direct-to-End-Consumer channel.
Gross margin in the first quarter of 2019 was 29.1%, down from 33.2% in the prior-year first quarter. Gross margins were constrained by the ongoing validation and qualification expense as well as excess capacity related to the recent manufacturing expansion.
Operating expenses for the first quarter were $7.9 million, compared to $7.1 million in the comparable prior-year period. The increase stemmed from increased advertising investments in our Direct-to-End-Consumer and support costs related to key new business development initiatives.
The company posted net income of approximately $775,000 or $0.08 per diluted share, versus approximately $769,000 or $0.10 per diluted share, for the 2018 first quarter.
2019 Guidance IntriCon reiterated its previously stated guidance for the full year 2019, which includes revenue of $128 million to $133 million and gross margins of 30.0% to 31.5%. The company continues to anticipate year-over-year revenue growth and gross margin improvement for the full year 2019 with the timing of certain orders related to its largest customer's on-going global commercial product launch now weighted towards the second half of the year.
Conference Call IntriCon's management team will hold a conference call today, Monday, April 29, 2019, beginning at 4:00 p.m. CT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 866-795-7248 for domestic callers or 470-495-9160 for international callers, using conference ID: 2084667. A live and archived webcast will be available on the "Investors" sections of the company's website at: www.IntriCon.com.
About IntriCon Corporation Headquartered in Arden Hills, Minn., IntriCon Corporation designs, develops and manufactures miniature and micro-miniature body-worn devices. These advanced products help medical, healthcare and professional communications companies meet the rising demand for smaller, more intelligent and better-connected devices. IntriCon has facilities in the United States, Asia, the United Kingdom and Europe. The company's common stock trades under the symbol "IIN" on the NASDAQ Global Market. For more information about IntriCon, visit www.intricon.com.
Forward-Looking Statements Statements made in this release and in IntriCon's other public filings and releases that are not historical facts or that include forward-looking terminology, including estimates of future results, are "forward-looking statements" within the meaning of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be affected by known and unknown risks, uncertainties and other factors that are beyond IntriCon's control, and may cause IntriCon's actual results, performance or achievements to differ materially from the results, performance and achievements expressed or implied in the forward-looking statements. These risks, uncertainties and other factors are detailed from time to time in the company's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2018. The company disclaims any intent or obligation to publicly update or revise any forward-looking statements, regardless of whether new information becomes available, future developments occur or otherwise.
Accounts receivable, less allowance for doubtful accounts of $368 at March 31, 2019 and $807 at December 31, 2018
10,493
11,479
Inventories
19,134
18,981
Contract assets
6,320
5,624
Other current assets
1,541
2,320
Total current assets
66,686
84,544
Machinery and equipment
38,202
37,161
Less: Accumulated depreciation
25,941
25,429
Net machinery and equipment
12,261
11,732
Goodwill
10,808
10,808
Intangible assets, net
2,546
2,585
Operating lease asset
5,518
-
Investment in partnerships
1,324
2,091
Long-term investments
15,228
-
Other assets, net
6,525
3,488
Total assets
$
120,896
$
115,248
Current liabilities:
Current financing leases
$
104
$
-
Current operating leases
1,700
-
Accounts payable
12,237
13,191
Accrued salaries, wages and commissions
2,572
4,409
Other accrued liabilities
4,692
4,047
Total current liabilities
21,305
21,647
Noncurrent financing leases
95
-
Noncurrent operating leases
4,030
-
Other postretirement benefit obligations
366
377
Accrued pension liabilities
733
706
Other long-term liabilities
1,306
544
Total liabilities
27,835
23,274
Commitments and contingencies
Shareholders' equity:
Common stock, $1.00 par value per share; 20,000 shares authorized; 8,714 and 8,664 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively
